The challenges of the implementation of the European Directive 2001/20/CE in the Main Member States

被引:3
|
作者
Libersa, C
Berger, F
Courcier-Duplantier, S
Marey, C
机构
[1] Fac Med Lille, Pharmacol Lab, F-59045 Lille, France
[2] Roche Pharma, Neuilly Sur Seine, France
[3] Inst Rech Int Servier, F-92415 Courbevoie, France
来源
THERAPIE | 2003年 / 58卷 / 06期
关键词
European Directive; clinical trials; transposition;
D O I
10.2515/therapie:2003089
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since the publication of Directive 2001/20/EC in the Official Journal of the European Communities on May 1, 2001, the Member States have been preparing its transposition into national legislation for application no later than May 2004. The discussions have proved to relate essentially to the organisation of the Ethics Committees, which must now give a single opinion per Member State, as well as to the time limits for obtaining this opinion and the authorisation for a study from the competent authority. These considerations have led to proposals of shorter time limits for products at an early stage of development or involving certain diseases. Despite harmonisation of the legislation, the application of the Directive does not eliminate all national differences.
引用
收藏
页码:549 / 551
页数:3
相关论文
共 50 条